Clinical Trials Directory

Trials / Sponsors / Molecular Insight Pharmaceuticals, Inc.

Molecular Insight Pharmaceuticals, Inc.

Industry · 19 registered clinical trials.

StatusTrialPhaseStarted
CompletedStudy to Evaluate 99mTc-MIP-1404 SPECT/CT Imaging in Men With Biopsy Proven Low-Grade Prostate Cancer
Prostate Cancer
Phase 32015-12-01
CompletedA Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology
Prostate Cancer
Phase 22012-08-01
Completed99mTc-MIP-1404 for Imaging Prostate Cancer: Phase I Clinical Study to Assess the Image Quality of a Simplified
Prostate Cancer
Phase 12012-07-01
CompletedA Phase 1 Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging to Histology in Men With Prostate Cancer
Prostate Cancer
Phase 12012-04-01
CompletedPilot Study of 99mTc-MIP-1404 SPECT/CT Imaging in Men With Prostate Cancer Undergoing Prostatectomy and/or Pel
Prostate Cancer
Phase 12012-01-01
WithdrawnA Pilot Study of 123I-MIP-1072 SPECT/CT Imaging With Optional Compact Gamma Camera Probe Imaging in Men With P
Prostate Cancer
—2011-03-01
CompletedA Study of 99mTc-MIP-1404 and 99mTc-MIP-1405 in Patients With Metastatic Prostate Adenocarcinoma and Healthy V
Prostate Cancer
Phase 12010-12-01
WithdrawnEfficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
Neuroblastoma
Phase 22010-01-01
TerminatedPhase I Safety and Dosimetry Study in Patients With Confirmed Metastatic Melanoma
Metastatic Melanoma
Phase 12009-12-01
CompletedA Phase I Pilot Study Comparing 123I MIP 1072 Versus 111In Capromab Pendetide in Subjects With Metastatic Pros
Prostate Cancer
Phase 12009-10-01
UnknownA Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/
Pheochromocytoma, Paraganglioma
Phase 22009-06-04
TerminatedContent Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma
Pheochromocytoma, Paraganglioma
—2009-04-01
WithdrawnStudy to Evaluate the Efficacy and Safety of 90Y-SMT487 in Subjects With Symptomatic Malignant Carcinoid Tumor
Malignant Carcinoid Tumor
Phase 22008-06-01
CompletedN2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
Neuroblastoma
Phase 22008-06-01
CompletedStudy to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate
Prostate Cancer
Phase 12008-05-01
CompletedSafety and Efficacy Iodofiltic Acid I 123 in the Treatment of Acute Coronary Syndrome
Acute Coronary Syndrome
Phase 22007-05-01
CompletedPhase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
Pheochromocytoma, Paraganglioma
Phase 1 / Phase 22007-04-01
CompletedULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoi
Pheochromocytoma, Paraganglioma, Carcinoid
Phase 12006-06-01
Approved For MarketingExpanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Parag
Pheochromocytoma, Paraganglioma
——